In re Bystolic Antitrust Litigation

CourtDistrict Court, S.D. New York
DecidedJanuary 15, 2021
Docket1:20-cv-05735
StatusUnknown

This text of In re Bystolic Antitrust Litigation (In re Bystolic Antitrust Litigation) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Bystolic Antitrust Litigation, (S.D.N.Y. 2021).

Opinion

USDC SDNY DOCUMENT SOUTHERN DISTRICT OF NEW YORK DOC #: nn nnn nn nana nna ccna naan sans ncccncnncnns KK DATE FILED:___1/15/2021 In re Bystolic Antitrust Litigation :

: 20-cv-5735 (LJL) This Order relates to: All Actions ORDER

nnn nnn eee LEWIS J. LIMAN, United States District Judge: Before the Court is a motion to transfer venue in two related sets of consolidated, putative class-action cases involving alleged antitrust violations in connection with the anti-hypertension drug Bystolic. For the following reasons, the motion to transfer venue is denied. BACKGROUND There are two sets of lawsuits before the Court. The first set of lawsuits are brought by direct purchasers of Bystolic and generic equivalents (“Direct Purchaser Actions”). Dkt. No. 111. The second set of lawsuits are brought by indirect purchasers of Bystolic (together with direct purchasers, “Plaintiffs”), which include consumers, health insurers, and welfare plans (“End Payor Actions”). Dkt. No. 113. The lawsuits are brought against the manufacturers and marketers of Bystolic (the “Forest Defendants”)! and other drug manufacturers (“Generic Defendants”) (collectively, “Defendants”). The Forest and Generic Defendants allegedly

' The Forest Defendants are defined as AbbVie Inc., Allergan, Inc., Allergan Sales, LLC, Allergan USA, Inc., Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., Forest Laboratories Ireland, Ltd., and Forest Laboratories, LLC. The Generic Defendants are defined as Hetero USA Inc., Hetero Labs Ltd., Hetero Drugs Ltd.

entered into anticompetitive settlement and license agreements that had the effect of delaying the production of generic equivalents to Bystolic; Plaintiffs allege that had such equivalents been able to enter the market earlier, the price of Bystolic would have decreased, benefitting consumers.3 The first action filed in this district was an End Payor Action filed on July 17, 2020 by the City of Providence against the Forest Defendants. See City of Providence v. AbbVie Inc.,

No. 20-cv-5538 (S.D.N.Y. July 17, 2020), Dkt. No. 1. Six days later, on July 23, 2020, the first Direct Purchaser action was filed as a related action under the instant case number by J M Smith Corp. against the Forest and Generic Defendants. See Dkt. No. 1.4 The remaining consolidated and coordinated cases were subsequently filed as related to those actions. Defendants argue that these cases should be transferred to the District of New Jersey principally because (1) none of the Defendants are located in this district while 11 of the 14 U.S.-based Defendants are headquartered in the District of New Jersey; (2) third parties implicated in the complaint, including generic producers that would have entered as competitors but for the allegedly improper agreements, are located in New Jersey; (3) only two of the named

Plaintiffs reside in this district; and (4) “[t]he purported Generic Defendants’ decision to delay was made in New Jersey and elsewhere (not New York).” Dkt. No. 80 at 9. Defendants also argue that because these cases are brought as nationwide class actions, Plaintiffs’ choice of

Torrent Pharmaceuticals Ltd., Torrent Pharma Inc., Alkem Laboratories Ltd.; Indchemie Health Specialties Private Ltd.; Glenmark Generics Inc., USA, Glenmark Generics Ltd., Glenmark Pharmaceuticals S.A.; Amerigen Pharmaceuticals, Inc., Amerigen Pharmaceuticals, Ltd.; Watson Laboratories, Inc. (NV), Watson Laboratories, Inc. (DE), Watson Laboratories, Inc. (NY), Watson Laboratories, Inc. (CT), Watson Pharma, Inc., Watson Pharmaceuticals Inc., Actavis, Inc., Teva Pharmaceutical Industries Ltd., and Teva Pharmaceuticals USA, Inc.. 3 For a more detailed summary of the facts alleged in the complaints, see Dkt. No. 50 at 3-5. 4 J M Smith Corp. had originally filed its complaint in the Northern District of California, see M Smith Corp. v. AbbVie Inc., No. 20-cv-4581 (N.D. Cal. July 23, 2020), but it dismissed that action and filed the instant action as related after City of Providence filed its action at No. 20-cv- 5538. forum should carry less weight. For the reasons that follow, Defendants’ arguments do not carry their burden to establish that a transfer is warranted. LEGAL STANDARD Under Section 1404(a) of the United States Code, “[f]or the convenience of parties and witnesses, in the interest of justice, a district court may transfer any civil action to any other

district or division where it might have been brought or to any district or division to which all parties have consented.” 28 U.S.C. § 1404(a). The statute codifies the doctrine of forum non conveniens for the federal system and provides for “transfer, rather than dismissal, when a sister federal court is the more convenient place for trial of the action.” Sinochem Int’l Co. v. Malaysia Int’l Shipping Corp., 549 U.S. 422, 430 (2007). To determine whether transfer is appropriate, the Court applies a two-step inquiry. First, it determines whether the action could have been brought in the proposed transferee court. Second, the Court “‘balances the private and public interests,’ to determine whether transfer is warranted ‘[f]or the convenience of parties and witnesses, [and] in the interest of justice.’” Inventel Prods. LLC v. Penn LLC, 2017 WL 818471, at *2 (S.D.N.Y. Feb. 28, 2017) (quoting

Gross v. British Broad. Corp., 386 F.3d 224, 230 (2d Cir. 2004); 28 U.S.C. § 1404(a)). These cases are brought pursuant to federal and state antitrust laws, and it is undisputed that they could have been filed instead in the District of New Jersey pursuant to 28 U.S.C. § 1331. The question presented turns on the balance of the private and public interests. “Among the factors to be considered in determining whether to grant a motion to transfer venue are, inter alia: (1) the plaintiff’s choice of forum, (2) the convenience of witnesses, (3) the location of relevant documents and relative ease of access to sources of proof, (4) the convenience of parties, (5) the locus of operative facts, (6) the availability of process to compel the attendance of unwilling witnesses, and (7) the relative means of the parties.” N.Y. Marine & Gen. Ins. Co. v. Lafarge N. Am., Inc., 599 F.3d 102, 112 (2d Cir. 2010) (quoting D.H. Blair & Co., Inc. v. Gottdiener, 462 F.3d 95, 106-07 (2d Cir. 2006)). “[T]he party requesting transfer carries the ‘burden of making out a strong case for transfer.’” Id. at 114 (quoting Filmline (Cross–Country) Prods., Inc. v. United Artists Corp., 865 F.2d 513, 521 (2d Cir. 1989)). Accordingly, “district courts in our Circuit have consistently

applied the clear and convincing evidence standard in determining whether to exercise discretion to grant a transfer motion,” id. (collecting cases), and operate with considerable discretion, see Forjone v. California, 425 F. App’x 73, 74 (2d Cir. 2011) (“The determination whether to grant a change of venue requires a balancing of conveniences, which is left to the sound discretion of the district court.”) (quoting Filmline, 865 F.2d at 520).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gulf Oil Corp. v. Gilbert
330 U.S. 501 (Supreme Court, 1947)
Koster v. (American) Lumbermens Mutual Casualty Co.
330 U.S. 518 (Supreme Court, 1947)
Forjone v. The State of California
425 F. App'x 73 (Second Circuit, 2011)
Blair & Co., Inc. v. Gottdiener
462 F.3d 95 (Second Circuit, 2006)
De Jesus v. National RR Passenger Corp.
725 F. Supp. 207 (S.D. New York, 1989)
Totilo v. Herbert
538 F. Supp. 2d 638 (S.D. New York, 2008)
Wellington Computer Graphics, Inc. v. Modell
315 F. Supp. 24 (S.D. New York, 1970)
Schwartz v. Marriott Hotel Services, Inc.
186 F. Supp. 2d 245 (E.D. New York, 2002)
In Re Hanger Orthopedic Group, Inc. Securities Litigation
418 F. Supp. 2d 164 (E.D. New York, 2006)
DiRienzo v. Philip Services Corp.
294 F.3d 21 (Second Circuit, 2002)
Flood v. Carlson Restaurants Inc.
94 F. Supp. 3d 572 (S.D. New York, 2015)
Starr Indem. & Liab. Co. v. Brightstar Corp.
324 F. Supp. 3d 421 (S.D. Illinois, 2018)
Pecorino v. Vutec Corp.
934 F. Supp. 2d 422 (E.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
In re Bystolic Antitrust Litigation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-bystolic-antitrust-litigation-nysd-2021.